Join us in this episode of the Oncology Brothers podcast as we dive deep into the rapidly evolving treatment landscape for small-cell lung cancer. Hosted by community oncologists Drs. Rahul and Rohit Gosain, we are thrilled to welcome Dr. Ticiana Leal, a thoracic medical oncologist from the Winship Cancer Institute - Emory University.
In this episode, we covered:
• Current treatment paradigm of small cell lung cancer, in localized setting and extensive stage.
• We covered the recent approval of durvalumab in limited stage setting post chemoRT.
• We touched on the role of growth factors, and how they get rarely utilized, and covered use of Trilaciclib.• Stressed the importance of immunotherapy in extensive stage with choices of Atezolizumab and Durvalumab, and touched on extended survival data with Atezolizumab
• Talked about logistical issues and uptake of Tarlatamab post approval.
• Stressed the importance of clinical trials to move the field ahead.
Whether you're a practicing oncologist or simply interested in the latest advancements in cancer treatment, this episode is packed with valuable information to help guide your practice.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!
